Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05268614 · ClinicalTrials.gov registry record · Phase 2
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
A Phase 2 study of Oropharyngeal Squamous Cell Carcinoma, sponsored by University of Florida.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 3
- Study locations
NCT05268614: Recruiting Phase 2 study of Oropharyngeal Squamous Cell Carcinoma, sponsored by University of Florida.
NCT05268614 is a Phase 2 study of Oropharyngeal Squamous Cell Carcinoma that is actively recruiting participants, run by University of Florida. The registered enrollment target is 250 participants, above the 199-participant average among 14 other Oropharyngeal Squamous Cell Carcinoma trials with a reported enrollment target (26% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05268614, a Phase 2 study of Oropharyngeal Squamous Cell Carcinoma, is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating free HPV DNA (cfHPV DNA) level, and cfHPV DNA clearance rate produces Local-Regional Control rates that are similar to what has been achieved with more aggressive therapy in patients with Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma (OPSCC).
Primary Outcome
Determine the Local-Regional Control Rate, defined as the absence of recurrence of OPSCC at the primary site or in a neck node that was included in a radiation therapy target volume
Conditions Studied
Interventions
- DRUG Cisplatin
- RADIATION Radiation therapy
Study Locations (3)
Florida
- University of Florida - Gainesville
- UF Health Proton Therapy Institute - Jacksonville
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2022-05-16 |
| Est. Completion | 2032-06 |
| Phase | Phase 2 |
What NCT05268614 shows while recruiting
NCT05268614 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 199-participant average among 14 other Oropharyngeal Squamous Cell Carcinoma trials with a reported enrollment target (26% higher).
The record links to 1 condition, with Oropharyngeal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Cisplatin is the first listed.
NCT05268614 reports a single indexed study location in Florida, South Carolina.
Frequently Asked Questions
What is clinical trial NCT05268614 about?
NCT05268614 is a clinical study titled "Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma". This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating free HPV DNA (cfHPV DNA) level, and cfHPV DNA clearance rate produces L...
What is the current status of trial NCT05268614?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2022-05-16. Estimated completion is 2032-06.
What conditions does trial NCT05268614 study?
This clinical trial studies the following conditions: Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05268614?
The interventions under investigation include: Cisplatin (DRUG), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT05268614?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05268614 being conducted?
This trial has 3 study locations across Florida, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharyngeal Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05268614's enrollment target sits among peer trials
250 4th of 14 higher than 11 of 14 other Oropharyngeal Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Oropharyngeal Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
RECRUITING · Phase 2
-
Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.
RECRUITING · Phase 2
-
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RECRUITING · Phase 2
-
Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma
RECRUITING · Phase 2
-
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RECRUITING · Phase 2
-
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI